ZA931560B - Ethers - Google Patents

Ethers

Info

Publication number
ZA931560B
ZA931560B ZA931560A ZA931560A ZA931560B ZA 931560 B ZA931560 B ZA 931560B ZA 931560 A ZA931560 A ZA 931560A ZA 931560 A ZA931560 A ZA 931560A ZA 931560 B ZA931560 B ZA 931560B
Authority
ZA
South Africa
Prior art keywords
pct
compounds
tnf
alkoxy
sec
Prior art date
Application number
ZA931560A
Other languages
English (en)
Inventor
Garry Fenton
Jonathan Stephen Mason
Malcom Norman Palfreyman
Andrew James Ratcliffe
Original Assignee
Rhone Oulenc Rorer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Oulenc Rorer Limited filed Critical Rhone Oulenc Rorer Limited
Publication of ZA931560B publication Critical patent/ZA931560B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA931560A 1992-03-04 1993-03-04 Ethers ZA931560B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929204808A GB9204808D0 (en) 1992-03-04 1992-03-04 Novel compositions of matter

Publications (1)

Publication Number Publication Date
ZA931560B true ZA931560B (en) 1994-05-11

Family

ID=10711570

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931560A ZA931560B (en) 1992-03-04 1993-03-04 Ethers

Country Status (12)

Country Link
US (1) US5541219A (xx)
EP (1) EP0629197B1 (xx)
JP (1) JPH07504201A (xx)
AT (1) ATE157092T1 (xx)
AU (1) AU3640793A (xx)
CA (1) CA2130938A1 (xx)
DE (1) DE69313267T2 (xx)
GB (1) GB9204808D0 (xx)
IL (1) IL104959A0 (xx)
MX (1) MX9301214A (xx)
WO (1) WO1993018024A1 (xx)
ZA (1) ZA931560B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311282D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996024350A1 (de) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Pharmazeutische präparate zur tnf-inhibition
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EA006685B1 (ru) 1999-08-21 2006-02-24 Алтана Фарма Аг Синергетическая композиция
CN1146562C (zh) * 1999-10-25 2004-04-21 奥坦纳医药公司 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
DE19954569A1 (de) * 1999-11-12 2001-05-17 Schwabe Willmar Gmbh & Co Pharmakologisch aktive Tetrahydrothiopyran-4-ol-Derivate, Verfahren zu ihrer Herstellung und Verwendung
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794026A (en) * 1955-04-11 1957-05-28 Dow Chemical Co Thiapyrylium and thiophenium compounds
US3558641A (en) * 1967-10-06 1971-01-26 Merck & Co Inc Certain pyridyl salicylic acid derivatives
US3657432A (en) * 1969-06-25 1972-04-18 Merck & Co Inc Anti-inflammatory salicylic acid derivatives
FR2187308B1 (xx) * 1972-06-01 1975-08-08 Roussel Uclaf
US3832354A (en) * 1972-08-01 1974-08-27 Sandoz Ltd 4-hydroxy-5-phenyl-3-thiophene acetic acids and their derivatives
US4198519A (en) * 1976-07-30 1980-04-15 Beecham Group Limited Anti-inflammatory compounds
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US5149828A (en) * 1987-09-30 1992-09-22 Ciba-Geigy Ag Stabilizers for color photography recording materials
US4778819A (en) * 1988-01-27 1988-10-18 Uniroyal Chemical Company, Inc. 2-(tetrahydro-2-thienyl)phenols and carbamate derivatives thereof
US5030647A (en) * 1990-02-09 1991-07-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-inflammatory thienylbenzylamine compounds
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5358938A (en) * 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase

Also Published As

Publication number Publication date
WO1993018024A1 (en) 1993-09-16
MX9301214A (es) 1994-03-31
IL104959A0 (en) 1993-07-08
EP0629197B1 (en) 1997-08-20
JPH07504201A (ja) 1995-05-11
CA2130938A1 (en) 1993-09-16
DE69313267D1 (en) 1997-09-25
US5541219A (en) 1996-07-30
AU3640793A (en) 1993-10-05
EP0629197A1 (en) 1994-12-21
ATE157092T1 (de) 1997-09-15
GB9204808D0 (en) 1992-04-15
DE69313267T2 (de) 1998-02-26

Similar Documents

Publication Publication Date Title
ZA931560B (en) Ethers
GB9202791D0 (en) Compounds
IL105219A0 (en) Cyclohexane-ylidene compounds and pharmaceutical compositions containing them
HU9500265D0 (en) Inhibitors of c-amp phosphodiesterase and tnf
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
PT73879B (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
CA2078221A1 (en) Pharmaceutical compositions comprising taurolidine and/or taurultam
ATE188965T1 (de) Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
FR2721608B1 (fr) Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
KR870700599A (ko) 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도
IL92358A0 (en) Diaryl compounds,their preparation and pharmaceutical compositions containing them
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
FR2500303B1 (xx)
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
TW261605B (xx)
AU3524795A (en) Aromatic ethers derived from indols such as 5ht1-like ligands
FR2700165B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
RU94040719A (ru) 2,3,4,5-тетрагидро-1h-3-бензазепины, фармацевтическая композиция, способ лечения и способ получения
ATE306260T1 (de) Monomere der 4,4-(disubstituierten)cyclohexan-1- ole und verwandte verbindungen